a collection of information unless it contains a valid OMB control number.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

Application Number		10646473			
Filing Date		2003-08-21			
First Named Inventor	Jamie	WAKEAM et al.			
Art Unit		2625			
Examiner Name	Singh	, S.			
Attorney Docket Numb	er	003797.00616			

				U.S.	PATENTS	Remove
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	6377259	B2	2002-04-23	Tenev et al.	
	2	5587560		1996-12-24	Crooks et al.	
3		5600634		1997-02-04 Howard		
	4	5799315		1998-08-25	Rainey et al.	
	5	6240414		2001-05-29	Beizer et al.	
	6	7106905		2006-09-12	Smske	
	7	5806074		1998-09-08	Souder et al.	
	8	6687876		2004-02-03	Schillit et al.	

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10646473		
Filing Date		2003-08-21		
First Named Inventor	Jamie	WAKEAM et al.		
Art Unit		2625		
Examiner Name Singh		, S.		
Attornou Docket Number		003797 00646		

U.S.PATENT APPLICATION PUBLICATIONS Remove													
Examiner Initial*	Cite No	Public	ation Number	Kind Code <sup>1</sup>	Code 1 Date   Name of Patentee or Applicant   F					Releva		Lines where ges or Relev	
	1	20020	085002	A1	2002-07	-04	Lamping et al.						
	2	20020	191452	A1	2002-12	-19 Fujihara							
If you wish	h to a	dd addi	tional U.S. Publi	shed Ap	plication	citatio	n information p	lease clic	k the Ad	d buttor	n. Add		
					FORE	SN PAT	TENT DOCUM	ENTS			Remove		
Examiner Initial*	Cite No	Foreig Numb	gn Document er <sup>3</sup>	Country Code <sup>2</sup>			e or	where Re	or Relevant	т.			
	1	09023	79	EP		A2	1999-03-17 Xerox Corp.		īp.				×
If you wish	h to a	dd addi	tional Foreign Pa	atent Do	cument	citation	information pl	ease click	the Add	button	Add		
				NON	I-PATE	NT LITE	RATURE DO	CUMENT	s		Remove		
Examiner Initials*	Cite No	(book	le name of the a , magazine, journ her, city and/or o	nal, seri	al, symp	osium,	catalog, etc), d						Ţδ
	1												
If you wisl	h to a	dd addi	tional non-paten	t literatu	re docu	ment cit	ation informati	on please	click the	Add b	utton A	dd	
					EX	AMINE	R SIGNATUR	E					
Examiner	Signa	ture						Date	Conside	ered			
			eference considerance and not										

	Application Number		10646473	
	Filing Date		2003-08-21	
INFORMATION DISCLOSURE	First Named Inventor Jamie		e WAKEAM et al.	
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Art Unit		2625	
(NOCION SUBMISSION UNICE ST OF K 1.33)	Examiner Name Si		I, S.	
	Attorney Docket Numb	er	003797.00616	

See find. Codes of USPTO Planto Tocuments at view, USPTO, DOV or MPEP 901.04. \* Enter office that all essed the document, by the lock bits crock (WPO) Standard ST3.3. \*\* Frequence painted consenset, the inclusion on the pase of the region of the Engerer mean proceed the sensel number of the pasent of sensel number of the pasent observable. \*
\*\*India of coursent by the appropriate symbots as indicated on the document under WPO Standard ST.16 if possible. \*
\*\*Applicant is to place a check mark here if English targuage translations a statistical.\*\*

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)

	Application Number		10646473		
			2003-08-21 WAKEAM et al.		
	Art Unit		2625		
Examiner Name Singh		Singh	I, S.		
Attorney Docket Number			003797 00616		

#### CERTIFICATION STATEMENT

Diagra can	37	CFR .	1 97	and	1 02	to make	the	appropriate	colortion/s	٠ŀ٠

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.57(e)(1).

### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1/56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1/97(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/Gary D. Fedorochko/	Date (YYYY-MM-DD)	2007-08-10
Name/Print	Gary D. Fedorochko	Registration Number	35509

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for lie fand by the USPTO to process) an application. Confidentiality is governed by \$5.1.S.C. 12.04 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence; P.O. Box 1450, Alexandria, V.S. 231-1450, D.NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, V.S. 2211-1450.

### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the stacked form related to a petient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is civulating; and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or cosmisting your submission related to a patient agricultant or patient. If you do not furnish the requested process and the process of the process and the process of the pro

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these cords.
  - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
  - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
  - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
  - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
    may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
    to the Patent Cooperation Treaty.
  - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
  application pursuant to 35 U.S.C. 12(2) to rissuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
  disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
  which became abandoned or in which the proceedings were terminated and which application is referenced by either a
  published application, an application open to public inspections or as issued patent.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.